Related by context. All words. (Click for frequent words.) 70 Zenvia ™ 66 Zenvia TM 66 pseudobulbar affect PBA 65 candidate Zenvia 65 Dyloject TM 64 Neurodex 63 ONCONASE R 63 including eniluracil ADH 63 Phase #b/#a clinical 63 PNP inhibitor 63 lintuzumab SGN 63 intravenous acetaminophen 62 Zemiva TM 62 JZP 61 opioid induced bowel dysfunction 61 candidate XP# 61 sNDA submission 61 generation purine nucleoside 61 Personalized Immunotherapy 61 Pegloticase 61 histone deacetylase HDAC inhibitor 61 omacetaxine mepesuccinate 61 AAG geldanamycin analog 61 Spiegelmer ® 61 octreotide implant 61 prokinetic agent 61 LymphoStat B TM 61 overactive bladder AA# 61 oral prodrug 61 TELINTRA 61 ruxolitinib 60 torezolid phosphate 60 Phase IIb clinical trials 60 Soliris TM eculizumab 60 alvespimycin 60 Oxytrex TM 60 dirucotide MBP# 60 refractory chronic lymphocytic 60 registrational 60 CB2 selective receptor agonist 60 Phase Ib study 60 ALN TTR 60 targeted radiotherapeutic 60 Zenvia Phase III 60 phase IIb clinical 60 Annamycin 60 Files Investigational 60 compound INCB# 60 Panzem R 60 BLA filing 60 diabetic neuropathic pain 60 Perceiva 60 dextromethorphan quinidine 60 BRILINTA 60 Linjeta TM 60 proprietary transdermal patch 60 ALN PCS 60 rALLy clinical trial 60 histamine dihydrochloride 60 acetonide FA 60 recombinant PSMA vaccine 59 diabetic peripheral neuropathic DPN 59 subcutaneous formulation 59 QNEXA ® 59 Diabetic Macular Edema 59 Empatic TM 59 Archexin 59 ATPace TM 59 Major Depressive Disorder MDD 59 Panzem ® 59 phase IIb trial 59 Androxal TM 59 PDE4 inhibitor 59 Zelrix 59 MKC# MT 59 severe hypercholesterolemia 59 Diabetic Macular Edema DME 59 ARIKACE ™ 59 vapreotide acetate 59 PANVAC VF 59 novel histone deacetylase 59 NP2 Enkephalin 59 XP# XP# 59 SUTENT ® 59 delivers fluocinolone acetonide FA 59 lucinactant 59 clinical trials Archexin 59 systemic anaplastic large 59 SinuNase TM 59 ALGRX 59 Elagolix 59 Zingo TM 59 Troxatyl TM 59 MAGE A3 ASCI 59 Solazed TM 59 investigational humanized monoclonal antibody 59 liposomal formulation 59 inhaled liposomal ciprofloxacin 59 Panzem R NCD 59 Xcytrin R 59 Phase Ib clinical trials 59 budesonide MMX ® 59 successfully commercialize Iluvien 59 TBC# 58 phase IIb III 58 REMOXY R 58 POSIDUR TM ELADUR TM 58 highly selective inhibitor 58 acyclovir Lauriad R 58 oral methylnaltrexone 58 Phase IIb III 58 application sNDA 58 RANK Ligand inhibitor 58 acute mania 58 receptor tyrosine kinase inhibitor 58 OvaRex R 58 Premarket Approval PMA 58 OLpur TM H2H 58 Pagoclone 58 opioid induced constipation OIC 58 PROVENGE sipuleucel T 58 tanespimycin 58 transmucosal delivery system 58 Iluvien ® 58 anticancer compound 58 Serdaxin ® 58 alvimopan 58 phase IIb study 58 Troxatyl 58 Enkephalin 58 REMOXY ® 58 Oracea TM 58 Traficet EN 58 recurrent herpes labialis 58 tezampanel NGX# 58 investigational hepatitis C 58 Generx ™ 58 ponatinib 58 MEND CABG II 58 TELINTRA R 58 Phase #b/#a trial 58 polyneuropathy HIV DSP 58 ELADUR ™ 58 riociguat 58 Initiates Enrollment 58 forodesine hydrochloride 58 confirmatory Phase III 58 Initiate Clinical Trial 58 HGS# 58 Alzhemed TM 58 ACUROX ® 58 FOLOTYN ® 58 SILENOR TM 58 Phase III confirmatory 58 Ketotransdel ® 58 hoFH 58 CRMD# 58 CYT# potent vascular disrupting 58 methylnaltrexone bromide 58 PI3K/Akt pathway inhibitor 58 Cannabinor 58 oral nucleoside analogue 58 OMNARIS HFA 58 Onconase 58 XL# anticancer compounds 58 Angiocept 58 dasatinib Sprycel ® 58 Safinamide 58 SUCCEED trial 58 dermal patch 58 TRANSDUR ® 58 Saforis 58 motexafin gadolinium Injection 58 IL# PE#QQR 58 CEQ# 57 OvaRex ® MAb 57 Drug Eluting Stent System 57 NUEDEXTA ™ 57 SILENOR 57 corticotropin injection 57 SNT MC# 57 lomitapide 57 orally administered inhibitor 57 LEP ETU 57 virus HCV protease inhibitor 57 Genasense ® oblimersen 57 Initiates Phase II 57 alpha 2A 57 Amigal TM 57 Lenocta TM 57 Chemophase 57 Trobalt 57 cannabinor 57 Plenaxis TM 57 Kamada AAT 57 HP Acthar Gel repository 57 ICA # 57 tiapamil 57 vinorelbine emulsion 57 Onrigin 57 Hsp# Inhibitor 57 ALN HPN 57 Serostim ® 57 MCSP respectively 57 norepinephrine reuptake inhibitor 57 Onco TCS 57 personalized cellular immunotherapy 57 ILUVIEN ® 57 Corlux 57 selective androgen receptor modulator 57 polycythemia vera essential thrombocythemia 57 albiglutide 57 MAA submission 57 SPRYCEL ® 57 IND Investigational New 57 alemtuzumab MS 57 GSK# [002] 57 budesonide MMX Phase III 57 EVIZON TM 57 Tarceva TM 57 Phase IIB 57 Hematide ™ 57 IMA# 57 Lu AA# 57 CD# CEA 57 ALVESCO R 57 myelodysplastic myeloproliferative diseases 57 IAP inhibitor 57 Avanafil 57 tezampanel 57 NDA Submission 57 Bosutinib 57 evaluating satraplatin 57 Initiates Phase III 57 treat opioid induced 57 Rhucin ® recombinant 57 Luramist TM 57 CIP TRAMADOL ER 57 BrachySil TM 57 ASONEP TM 57 include Phenoptin TM 57 visilizumab 57 MEK inhibitor RDEA# 57 selective A2A adenosine receptor 57 Phase 1a clinical 57 HCV NS5B polymerase 57 initiate Phase IIa 57 LymphoStat B belimumab 57 PEG PAL 57 Meets Primary Endpoint 57 Sphingomab TM 57 Vilazodone 57 intranasal formulation 57 TRANSDUR Sufentanil 57 candidate brentuximab vedotin 57 PrevOnco ™ 57 Phase #b/#a 57 DAYTRANA TM 57 topically applied SEPA 57 molecular imaging radiopharmaceutical 57 HCD# [002] 57 sNDAs 57 catheter occlusion 57 OMAPRO ™ 57 radiation sensitizer 57 desvenlafaxine succinate 57 DDP# 57 EDEMA3 trial 57 Octreolin 57 EVIZON TM squalamine lactate 56 fosbretabulin 56 Surfaxin LS 56 Luveniq 56 vinorelbine tartrate 56 CORT # 56 reslizumab 56 AeroLEF TM 56 AzaSite Plus 56 TLK# 56 Phase 1b clinical trials 56 forodesine 56 vidofludimus 56 ABILIFY Injection 56 opioid bowel dysfunction 56 hypoxia activated prodrug 56 Dacogen injection 56 TRX1 56 DPX Survivac 56 oxymorphone ER 56 GLP1 agonist 56 Genasense R oblimersen 56 ENRICH trial 56 BEMA Buprenorphine 56 Vascular Disrupting Agent 56 painful diabetic neuropathy 56 Biologic License Application BLA 56 JAK2 Inhibitor 56 JAK inhibitor 56 Dalbavancin 56 investigational pan BCR 56 elotuzumab 56 BEMA TM Fentanyl 56 Resten NG 56 oral ridaforolimus 56 Biologics License Application BLA 56 Acetavance TM intravenous acetaminophen 56 THR beta agonist 56 Evoltra ® 56 lorvotuzumab mertansine 56 arsenic trioxide injection 56 EVIZON ™ 56 MGd 56 LUVENIQ 56 Iloperidone 56 Ophena TM 56 Phase 2b Trial 56 octreotide acetate 56 Aurexis 56 candidate REP# 56 Cerebril TM 56 Gel repository corticotropin injection 56 non nucleoside inhibitor 56 Granted Orphan Drug 56 opioid induced constipation 56 vosaroxin 56 VEGFR2 inhibitor 56 novel VDA molecule 56 oral rivaroxaban 56 R#/MEM 56 postherpetic neuralgia PHN 56 Kuvan TM sapropterin 56 Completes Patient Enrollment 56 Ketotransdel 56 Cloretazine R VNP#M 56 gabapentin enacarbil 56 Biological License Application 56 Prodarsan R 56 Ketotransdel TM 56 preclinical pharmacokinetic 56 Vernakalant 56 PSN# [002] 56 thrombin component 56 Zorbtive TM 56 Augment TM 56 Zemplar Capsules 56 Tolvaptan 56 Contrave NDA 56 JAK2 inhibitor 56 Benlysta belimumab 56 Receives Orphan Drug Designation 56 tasimelteon 56 non constipation irritable 56 Cintredekin Besudotox 56 R#/MEM # 56 Pivotal Phase III 56 MyVax R 56 Entereg TM 56 ATryn ® 56 Prestara TM 56 vascular disrupting agent 56 Firazyr 56 Stavzor TM 56 SPARLON 56 BLA submission 56 Gabapentin GR 56 post herpetic neuralgia PHN 56 investigational antiplatelet agent 56 drug ISA# 56 granted Ortec 56 phase IIa clinical 56 Premarket Approval 56 APEX PD 56 Qutenza TM 56 SinuNase ™ 56 sapropterin dihydrochloride 56 dirucotide 56 FUSILEV ® 56 teduglutide 56 ABL inhibitor 56 severe gastroparesis 56 Phase IIIb clinical 56 markets HP Acthar 56 Simulect 56 IND submission 56 EMBEDA ™ 56 rALLy 56 PHX# 56 R Saizen R 56 PREOS R 56 ATL# [002] 56 pioglitazone HCl 56 investigational atypical antipsychotic 56 Lixivaptan 56 ALN HTT 56 Submits Supplemental 56 desvenlafaxine 56 Anturol ® 56 Cloretazine ® 56 HFA MDI 56 Entereg R 56 non alcoholic steatohepatitis 56 mGluR5 negative 56 Pirfenidone 56 5 lipoxygenase inhibitor 56 CINTREDEKIN BESUDOTOX 55 Investigational Device Exemption 55 Zolpimist 55 trastuzumab DM1 T DM1 55 cutaneous T 55 fidaxomicin Phase 3 55 PMA submission 55 postoperative ileus POI 55 lexidronam injection 55 gemcitabine Gemzar ® 55 ® decitabine 55 PLK1 SNALP 55 Prodarsan 55 Q#IR 55 Files IND 55 ancrod 55 Vicinium TM 55 zolpidem tartrate sublingual tablet 55 antibiotic candidate Ramoplanin 55 Trastuzumab DM1 55 Requip XL 55 sodium Injection 55 Pafuramidine 55 faropenem medoxomil 55 SAR# [004] 55 Iluvien TM 55 rhIGF-I/rhIGFBP-3 55 OMAPRO 55 ONSOLIS TM 55 Luramist 55 Fx #A 55 Azedra 55 markets Gelclair R 55 Phase IIa trials 55 novel trazodone formulation 55 SILENOR ™ 55 EGS# 55 VIVITROL ® 55 Anavex #-# 55 Initiated Phase 55 IMC A# 55 Allovectin 7 r 55 pralatrexate injection folate analogue 55 Ropinirole 55 huC# DM4 55 ospemifene 55 Initiate Phase 55 PS# DARA 55 iii GTx 55 Anturol TM 55 pan histone deacetylase 55 ORENCIA ® 55 Frova ® 55 miconazole Lauriad ® 55 Phase 2b clinical trials 55 EXPLORE Xa 55 ezogabine 55 Kit CD# positive 55 UPLYSO 55 BEMA Granisetron 55 OMNARIS 55 ELADUR 55 VitiGam 55 metastatic sarcomas 55 Inhalation Aerosol 55 balsalazide tablet 55 Fentanyl TAIFUN R 55 IMC #B 55 GALNS 55 dyskinesia PD LID 55 LEVADEX ™ 55 Trofex 55 proprietary intravenous formulation 55 rilonacept 55 samalizumab 55 ONGLYZA ™ 55 Phase IIa Clinical Trial 55 ZYBRESTAT fosbretabulin 55 enzyme rHuPH# 55 ACAPODENE 55 relapsed refractory multiple myeloma 55 Allovectin 7 55 Fentanyl Taifun 55 cystinosis patients 55 Sudhir Agrawal D.Phil 55 BNC# 55 generation URAT1 inhibitor 55 phase III ACCLAIM 55 intravenous methylnaltrexone 55 novel prodrug 55 rALLy trial 55 Augment Injectable 55 TACI Ig 55 ocular formulation 55 ISO Vorin TM 55 Neo Kidney Augment 55 GED aPC 55 brentuximab vedotin SGN 55 Phase lll 55 chronic idiopathic thrombocytopenic purpura 55 dexanabinol 55 XOMA 3AB 55 PDX pralatrexate 55 Convivia TM 55 tafamidis 55 vernakalant hydrochloride 55 ALN TTR# 55 Eniluracil 55 bicifadine 55 Glybera R 55 MEND CABG 55 Staccato loxapine 55 pafuramidine maleate 55 ZEVALIN ® 55 Friedreich Ataxia FRDA 55 oral opioid modulator 55 depressive episodes associated 55 Locteron ® 55 Fibrillex TM 55 eprodisate Fibrillex TM 55 DermaVir Patch 55 Omigard 55 formerly LymphoStat B 55 Soliris eculizumab 55 LibiGel ® 55 Octreotide 55 TKM PLK1 55 serotonin norepinephrine reuptake inhibitor 55 Silenor ® 55 compound ISA# 55 diarrhea predominant irritable 55 Zenvia 55 nalbuphine ER 55 recombinant biopharmaceutical 55 mitogen activated ERK kinase 55 KRYSTEXXA TM pegloticase 55 Exherin TM 55 autologous cellular immunotherapy 55 FDA APPROVES 55 refractory gout 55 P#X# antagonist 55 PEGylated interferon 55 Stavzor ™ 55 Tezampanel 55 refractory Hodgkin lymphoma 55 Kynapid 55 topical gel formulation 55 beta 1a 55 RhuDex TM 55 Solzira 55 inhaled antibiotic 55 dosing cohort 55 sarcoma melanoma 55 Phase IIa clinical trials 55 squalamine 55 dorzolamide 55 Efficacy Results 55 brivaracetam 55 RNAi Therapeutic 55 Marqibo 54 drug GAP #B# 54 dose escalation phase 54 Cloretazine 54 supplemental biologics 54 Solazed 54 Plicera 54 Polymer Microspheres 54 2A receptor agonist 54 Huntexil 54 INSPIRE Trial Phase III 54 KNS # 54 injectable formulation 54 PDE# inhibitors 54 Panzem 54 memantine HCl 54 EMPOWER ™ 54 pivotal bioequivalence 54 EmbraceAC 54 blinded randomized placebo controlled 54 gepirone ER 54 GLP1 INT TM 54 Cimzia TM 54 RhuDex ® 54 Factor VIIa 54 topically administered 54 Cleviprex TM clevidipine 54 QLT# 54 thorough QT 54 Phase 2a clinical trials 54 Onalta ™ 54 cell lymphoma CTCL 54 PrevOnco 54 Submits Biologics License Application 54 Application BLA 54 rasagiline tablets 54 DXL# 54 Metformin GR 54 non nucleoside HCV 54 Biologic License Application 54 Aryplase 54 RELOVAIR ™ 54 ACV1 54 Pruvel 54 T Pred 54 KRN# 54 small molecule tyrosine 54 ketoprofen patch 54 Silenor ® doxepin 54 SAR# [002] 54 Phase #/#a trial 54 EMPOWER Study 54 dose escalation clinical 54 AIMM trial 54 treat dysmenorrhea 54 SUPPRELIN R LA 54 Roflumilast 54 Orphan Status 54 Orathecin 54 HepeX B 54 Oral Calcitonin 54 vaginally administered lidocaine 54 Prostate AdenoCarcinoma Treatment 54 CG# [003] 54 Fodosine 54 Amrubicin 54 BRIM3 54 dihydrochloride Phase 3 54 Submits Response 54 IONSYS TM 54 HEPLISAV TM 54 EMPOWER TM 54 ORENCIA R 54 Veronate 54 individualized cellular immunotherapy 54 3 registrational trial 54 ApoB SNALP 54 orBec 54 rheumatoid arthritis psoriatic arthritis 54 Xcellerated T Cells 54 demonstrated antitumor activity 54 ULTRASE 54 Submits NDA 54 PROVENGE ® 54 Golimumab 54 confirmatory Phase 3 54 alpha antagonist 54 tramiprosate ALZHEMED TM 54 imexon 54 histone deacetylase inhibitor 54 Phase III ADT 54 PF # [002] 54 Emezine 54 ADVEXIN p# therapy 54 PRIMO CABG 54 tramiprosate Alzhemed TM 54 adecatumumab MT# 54 Daytrana ® 54 Curaxin CBLC# 54 HuMax TAC 54 RELISTOR ® 54 phase Ib 54 paliperidone palmitate 54 Phase 2b Clinical Trial 54 Thelin TM 54 StaphVAX R 54 huN# DM1 54 Stavzor 54 clinical endpoints 54 dihydrochloride Tablets 54 Prosaptide 54 Ofatumumab 54 indiplon capsules 54 GATTEX TM 54 E1 INT TM 54 sublingual tablets 54 allosteric modulator NAM 54 NUVIGIL 54 Icatibant 54 Telintra 54 Horizant ™ 54 torsemide ER 54 antibody MT# 54 MGCD# [001] 54 Targretin capsules 54 NDA submission 54 post operative ileus 54 VIAject R 54 Phase Ib IIa 54 Uvidem 54 Successfully Completes Phase 54 ITAX 54 Voraxaze 54 Investigational Treatment 54 CHOP chemotherapy 54 HDAC Inhibitor 54 NYSE Amex PTN 54 release intravitreal insert 54 Omapro 54 HepeX B TM 54 Pyridorin 54 Bazedoxifene 54 PD2i ® algorithm 54 zileuton CR 54 Market Authorization Application 54 GRALISE 54 multicenter Phase II 54 TransVax tm 54 Vertex hepatitis C 54 Phase III Clinical Trial 54 Maribavir 54 Prednisporin TM 54 GnRH antagonist 54 MAXY VII 54 phase IIa 54 Valtropin 54 allosteric modulator PAM 54 varespladib 54 Durezol TM 54 Phase 2a clinical 54 oral cladribine 54 tolevamer 54 OncoGel 54 assessing T DM1 54 mertansine 54 Nanobody 54 Bicifadine 54 relapsed MM 54 Neuromodulation System 54 Drug Candidate 54 NASDAQ CXSP announced 54 Phase IIb Trial 54 PEG SN# 54 PIX# trial 54 RAPTIVA 54 TRANSDUR TM Sufentanil 54 topical non steroidal 54 Hedgehog antagonist 54 Liposomal 54 Diamyd r 54 Premarket Approval Application 54 LEAPS H#N# 54 preclinical efficacy 54 Solzira TM 54 nasal calcitonin product 54 initiate multicenter 54 GLP toxicology studies 54 Mepact 53 Toremifene 53 aurora kinase 53 sterile lidocaine patch 53 solifenacin succinate 53 RSD# 53 Nasdaq VNDA 53 Somatuline R Autogel R 53 vemurafenib 53 budesonide foam 53 Ozarelix 53 LEVADEX TM 53 ADVANCE PD 53 erlotinib Tarceva ® 53 NEBIDO 53 IIb clinical trial 53 candidate NGX 53 Submits Investigational 53 treatmentof 53 REG2 53 NMDA antagonist 53 rufinamide 53 C1 INH deficiency 53 Application MAA 53 Insulin PH# 53 Zavesca r 53 Announces Tentative Approval 53 TMC# [002] 53 rusalatide acetate 53 Phase IIb clinical 53 midstage studies 53 paclitaxel poliglumex 53 oral ghrelin agonist 53 Phase III Pivotal 53 Ostabolin C TM 53 ACOMPLIA R 53 REVIVE TA 53 gastrointestinal disorders characterized 53 Testosterone MDTS R 53 ELACYT 53 IV APAP 53 Renvela ® 53 AKT inhibitor 53 DACH platinum 53 CIMZIA TM 53 Nebido 53 sorafenib tablets 53 Gralise 53 LibiGel testosterone gel 53 Topical Interferon Alpha 2b 53 diagnostic molecular imaging 53 RIGScan CR 53 GATTEX ® 53 vaccine GRNVAC1 53 vilazodone 53 NanoTab 53 HDL Selective Delipidation 53 Ceflatonin ® 53 midstage trials 53 apricitabine ATC 53 FDA Accepts 53 Valortim TM 53 Prodarsan ® 53 Perflubutane Polymer Microspheres 53 reliever tramadol 53 Diamyd ® 53 Marketing Authorization Application MAA 53 TRPV1 agonist 53 ALN VSP Phase 53 product platforms AZX# 53 liver resection surgeries 53 investigational drug 53 Ceplene TM 53 TRO# 53 hypoparathyroidism 53 Inc. AMEX YMI 53 Proxinium TM 53 CRF1 receptor antagonist 53 Glybera 53 sulodexide 53 % uracil topical 53 ORBIT II 53 Inc. Nasdaq VVUS 53 apoptosis inducer 53 ongoing Phase 1b 53 DOS# 53 Phase IIb Clinical Trial 53 EOquin 53 eltrombopag 53 Keppra ® XR 53 ARRY # 53 Urocidin TM 53 Hematide ™ peginesatide 53 compound PMX # 53 IV acetaminophen 53 FDA Approvable Letter 53 ZEGERID Chewable Tablets 53 subcutaneous methylnaltrexone 53 Arsenic trioxide 53 Tectin TM 53 ORE# 53 Fast Track Designation 53 antibody MAb 53 Aurora Kinase 53 romidepsin novel 53 Capesaris 53 dacetuzumab SGN 53 leading oral taxane 53 Ceflatonin 53 mGluR2 positive 53 Marketing Authorization Application 53 Kuvan R 53 Lauren Silvernail 53 Acetavance 53 Hepatitis C HCV 53 ENTEREG ® 53 sumatriptan DosePro 53 Risperidone Oral Solution 53 ALTROPANE R 53 Rhucin R 53 Investigational Oral 53 Femring ® 53 TYZEKA 53 sNDA filing 53 Raptiva R 53 ofatumumab HuMax CD# 53 NS5A 53 fluvoxamine maleate 53 Triapine R 53 SYCREST 53 Trimesta 53 candidate WF# 53 oral hydromorphone 53 Phase 2a Trial 53 THALOMID 53 NOX E# 53 Lucanix R 53 castrate resistant prostate cancer 53 Initiate Phase II 53 ON #.Na 53 inhaled formulation 53 registrational trial 53 PROMACTA 53 PREOS 53 LE SN# 53 IAP inhibitors 53 Actimmune ® 53 Behcet uveitis 53 Raptiva ® 53 HuLuc# 53 acyclovir Lauriad ® 53 Aurora kinase inhibitor 53 controlled multicenter Phase 53 BEMA ® 53 dose cohort 53 lenalidomide Revlimid R 53 ASONEP 53 Exocrine Pancreatic Insufficiency 53 haematologic 53 Opterone R 53 initiate Phase IIb 53 REGEN trial 53 L Annamycin 53 MBP# [001] 53 IMPACT DCM 53 QNEXA 53 incyclinide 53 Zybrestat 53 Surfaxin lucinactant 53 Acetavance TM 53 OFIRMEV 53 relapsing multiple sclerosis 53 MOZOBIL 53 cetrorelix pamoate 53 Phase 1b clinical 53 Familial Adenomatous Polyposis FAP 53 Novolimus 53 AeroLEF 53 indibulin 52 SCENESSE ® 52 NADiA ProsVue 52 TKM ApoB 52 orally dosed 52 MethyPatch 52 Divalproex Sodium 52 Alvesco R 52 lymphoid malignancies 52 TEMSO 52 AA amyloidosis 52 ThermoDox R 52 relapsed MCL 52 Deferiprone 52 PRECISE Trial 52 Neovasc Reducer 52 Phase III psoriasis 52 GRNVAC1 52 ZFP Therapeutics 52 Phase III multicenter 52 oral PTH 52 Pharmacokinetics PK 52 Augment ™ 52 Phase Ib clinical 52 GSK# [001] 52 Silodosin 52 IIa clinical trials 52 systemically administered 52 Amoxicillin PULSYS Phase III 52 CORT # estimates 52 Testosterone MDTS ® 52 AMPAKINE CX# 52 maturation inhibitor 52 TKB# 52 Allovectin 7 ® 52 INCB# [002] 52 LAF# 52 Omacetaxine 52 Marketing Authorisation Application MAA 52 CCR9 antagonist 52 XOPENEX HFA MDI 52 postapproval 52 thrombin inhibiting aptamer 52 keloid scarring 52 Phase 2b kidney transplant 52 Phase #/#a clinical 52 Ereska 52 human C1 inhibitor 52 XIAFLEX ™ 52 Phase IIa trial 52 herpes zoster shingles 52 long acting muscarinic 52 HuMax EGFr 52 Inhalation Solution 52 DIFICID ™ 52 BENLYSTA ® 52 ARIKACE 52 fibrotic disease 52 Phase III randomized controlled 52 MDS AML 52 EDEMA3 52 MIST II 52 novel therapeutic antibodies 52 Sanctura XR 52 Cand5 52 alkylating agent 52 obatoclax 52 herpetic keratitis 52 EGRIFTA TM 52 placebo controlled Phase III 52 Bioral Amphotericin B